FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry. A matrix tablet with a trimetazidine prolonged-release base contains a core comprising 8-12% trimetazidine or its pharmaceutically acceptable salt as an active ingredient and excipients being hypromellose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide with a dissolving coating. A trimetazidine tablet is prepared by direct compression technique with film coating.
EFFECT: according to the invention, the matrix tablet formulation enables improved homogeneity and dose accuracy, provides sustained release of trimetazidine for a long period of time and maintains the required blood plasma trimetazidine concentration.
5 cl, 6 tbl
